Abbott and AstraZeneca will advance the development of Abbott’s next-generation fenofibrate ABT-335 and AZ’s Crestor (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III trials. The single pill would target all three major blood lipids: LDL-C “bad” cholesterol, HDL-C “good” cholesterol, and triglycerides. Abbott’s ABT-335, currently in late-stage clinical trials, is part of a class of medications called fibrates, which have be...